Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma.
Change in tumor volume after chemotherapy appears to have a prognostic significance for the outcome of osteosarcoma. A newly developed volume measurement method based on three-dimensional summation with a proved reproducibility was utilized to measure osteosarcoma tumor volume. This retrospective analysis included 38 patients with biopsy- proven, nonsurface, skeletal high-grade osteosarcoma. The treatment was started by using three cycles of preoperative chemotherapy with cisplastin (100 mg/m2) and adriamycin (30 mg/m2). The tumor volume was measured before and after preoperative chemotherapy using three-dimensional magnetic resonance image measurement. The percentage of tumor necrosis was assessed by pathologic exam. After three cycle of postoperative chemotherapy, the patients were followed up at regular interval. For the 23 good responder patients, the mean survival time was 73.2 months (95% confidence interval 61.9-84.5 months), and for the 15 poor responder patients, the mean survival time was 50.8 months (95% confidence interval 38.6-63.1 months) (p<0.05). For the 14 patients with increased tumor volume after chemotherapy, the mean survival time was 47.5 months (range: 36.3-58.6 months) and for the 24 patients with stable or decreased tumor volume, the mean survival time was 74.3 months (range: 63.79-84.88 months) (p<0.05). Among the various factors, histopathologic response and tumor volume change after chemotherapy predicted disease free survival (p<0.05). Change in the tumor volume that was measured with a reproducible method and the histopathologic response after chemotherapy were the important predictors of disease free survival for osteosarcoma patients.
Moon
Seong-Hwan
SH
Department of Orthopaedic Surgery, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.
Shin
Kyoo-Ho
KH
Suh
Jin-Suck
JS
Yang
Woo-Ick
WI
Noh
Jae-Keong
JK
Hahn
Soo-Bong
SB
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D002945:Cisplatin / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D004317:Doxorubicin; D002945:Cisplatin
J Clin Oncol. 1992 Jan;10(1):5-15
1370176
J Clin Oncol. 1990 Dec;8(12):1988-97
2230890
Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3
2520314
Invest Radiol. 1992 May;27(5):367-73
1582820
Clin Radiol. 1994 Jan;49(1):19-23
8299327
Clin Radiol. 1995 Jun;50(6):384-90
7789022
J Clin Oncol. 1996 Mar;14(3):848-58
8622033
Clin Orthop Relat Res. 1997 Dec;(345):206-14
9418642
J Clin Oncol. 1998 Feb;16(2):658-63
9469355
Clin Orthop Relat Res. 2000 Jul;(376):200-8
10906876
Cancer. 1975 Dec;36(6):2179-91
1060506
Cancer. 1976 Jan;37(1):1-11
1082364
Arch Pathol Lab Med. 1977 Jan;101(1):14-8
299812
Mayo Clin Proc. 1978 Nov;53(11):695-700
280739
J Bone Joint Surg Am. 1980 Sep;62(6):1027-30
7000786
Cancer. 1982 Mar 15;49(6):1221-30
6174200
Clin Orthop Relat Res. 1982 Jul;(167):250-4
6954021
N Engl J Med. 1985 Dec 26;313(26):1637-43
3906399
AJR Am J Roentgenol. 1990 Apr;154(4):763-9
2107673
Radiology. 1990 Jun;175(3):791-6
2188300
Cancer. 1992 Feb 1;69(3):698-708
1730120